Performance of Roche qualitative HEV assay on the cobas 6800 platform for quantitative measurement of HEV RNA.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Anastasiou, Olympia E
MetadataShow full item record
AbstractBackground: Hepatitis E virus (HEV) infection is an increasingly recognized cause of acute and chronic hepatitis in high-income countries and is the most frequent cause of acute viral hepatitis in many European countries. Appropriate tools to detect and quantify HEV RNA are needed. This study aimed to evaluate the performance of the Roche cobas® HEV assay and compare it with the Fast Track Diagnostics (FTD) Hepatitis E RNA assay. Methods: HEV viral load determination and lower limit of detection (LOD, defined as the lowest amount of viral copies that could be detected in 95 % of repeats) were assessed using a WHO standard dilution panel, testing 240 samples of various concentrations. Reproducibility was tested at three different concentration levels, for different genotypes, and with different sample types (serum, plasma) in 30 samples. Sample stability was analyzed after three freeze/thaw cycles in 25 samples. Results: Cobas HEV assay showed a strong linear relationship between log of HEV WHO dilution series and Ct values over the reportable range from 200-5000 IU/mL HEV RNA copies. The amplification efficiency was higher than 92 %. LOD was 22 IU/mL (95 % CI: 17.4-31.8) and reproducibility tests showed a 100 % nucleic acid test (NAT) reactivity of cobas HEV for WHO dilution series (range 200-5000 IU/mL, n = 90). Cobas HEV assay detected all different HEV genotypes from biobank samples irrespective of the sample type. NAT reactivity of cobas HEV was not affected by three freeze/thaw cycles. Conclusions: Roche cobas HEV assay is a powerful NAT tool in terms of robustness, reproducibility and linearity. It is a feasible alternative for high-volume testing.
CitationJ Clin Virol. 2020;129:104525. doi:10.1016/j.jcv.2020.104525.
AffiliationCIIM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.
JournalJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Analytical characteristics and comparative evaluation of Aptima HCV quant Dx assay with the Abbott RealTime HCV assay and Roche COBAS AmpliPrep/COBAS TaqMan HCV quantitative test v2.0.
- Authors: Worlock A, Blair D, Hunsicker M, Le-Nguyen T, Motta C, Nguyen C, Papachristou E, Pham J, Williams A, Vi M, Vinluan B, Hatzakis A
- Issue date: 2017 Apr 4
- Development of a World Health Organization International Reference Panel for different genotypes of hepatitis E virus for nucleic acid amplification testing.
- Authors: Baylis SA, Hanschmann KO, Matsubayashi K, Sakata H, Roque-Afonso AM, Kaiser M, Corman VM, Kamili S, Aggarwal R, Trehanpati N, Gärtner T, Thomson EC, Davis CA, da Silva Filipe A, Abdelrahman TT, Blümel J, Terao E, HEV collaborative study group.
- Issue date: 2019 Oct
- Performance evaluation of the DAAN HCV assay for quantification of hepatitis C virus RNA and its comparison with COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, v2.0.
- Authors: He Y, Wang Y, Chen X, Huang H, Deng J, Chen P, Bin H
- Issue date: 2020 Mar 13
- Hepatitis E virus blood donor NAT screening: as much as possible or as much as needed?
- Authors: Vollmer T, Diekmann J, Knabbe C, Dreier J
- Issue date: 2019 Feb
- Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay.
- Authors: Ronsin C, Pillet A, Bali C, Denoyel GA
- Issue date: 2006 Apr